MA55607A - Inducteurs de la ho-1 - Google Patents
Inducteurs de la ho-1Info
- Publication number
- MA55607A MA55607A MA055607A MA55607A MA55607A MA 55607 A MA55607 A MA 55607A MA 055607 A MA055607 A MA 055607A MA 55607 A MA55607 A MA 55607A MA 55607 A MA55607 A MA 55607A
- Authority
- MA
- Morocco
- Prior art keywords
- inductors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962833031P | 2019-04-12 | 2019-04-12 | |
| US201962932629P | 2019-11-08 | 2019-11-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA55607A true MA55607A (fr) | 2022-02-16 |
Family
ID=70465543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA055607A MA55607A (fr) | 2019-04-12 | 2020-04-08 | Inducteurs de la ho-1 |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US20220177460A1 (fr) |
| EP (1) | EP3952990A1 (fr) |
| JP (2) | JP2022527402A (fr) |
| KR (1) | KR20220010491A (fr) |
| CN (1) | CN113874074B (fr) |
| AU (1) | AU2020271833A1 (fr) |
| BR (1) | BR112021020055A2 (fr) |
| CA (1) | CA3135615A1 (fr) |
| CO (1) | CO2021012287A2 (fr) |
| IL (1) | IL287183B2 (fr) |
| MA (1) | MA55607A (fr) |
| MX (1) | MX2021012466A (fr) |
| PH (1) | PH12021552348A1 (fr) |
| SG (1) | SG11202110595YA (fr) |
| TW (1) | TW202104211A (fr) |
| WO (1) | WO2020210339A1 (fr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8759535B2 (en) | 2010-02-18 | 2014-06-24 | High Point Pharmaceuticals, Llc | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof |
| ES2679918T3 (es) | 2010-02-18 | 2018-08-31 | Vtv Therapeutics Llc | Derivados de imidazol condensados sustituidos, composiciones farmacéuticas y métodos de uso de los mismos |
| EP3876939A4 (fr) | 2018-11-07 | 2022-08-10 | Dana-Farber Cancer Institute, Inc. | Dérivés benzothiazoles et dérivés 7-aza benzothiazoles comme inhibiteurs de la janus kinase 2 et leurs utilisations |
| JP7603011B2 (ja) * | 2019-01-18 | 2024-12-19 | ブイティーブイ・セラピューティクス・エルエルシー | 置換縮合イミダゾール誘導体並びに鎌状赤血球症及び関連する合併症を処置する方法 |
| US20220177460A1 (en) | 2019-04-12 | 2022-06-09 | Mitobridge Inc. | Hmox1 inducers |
| US11691963B2 (en) | 2020-05-06 | 2023-07-04 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors |
| US11623918B2 (en) | 2020-11-18 | 2023-04-11 | Southern Research Institute | Compounds for the treatment of acute and chronic kidney disease |
| WO2022109066A1 (fr) * | 2020-11-18 | 2022-05-27 | Southern Research Institute | Composés pour le traitement d'une néphropathie aiguë et chronique |
| TW202241889A (zh) | 2020-12-23 | 2022-11-01 | 美商雅捷可斯治療公司 | 作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑 |
| WO2022174384A1 (fr) | 2021-02-19 | 2022-08-25 | Mitobridge, Inc. | Sels et formes cristallines d'un inducteur hmox1 |
| US12162881B2 (en) | 2021-11-09 | 2024-12-10 | Ajax Therapeutics, Inc. | Forms and compositions of inhibitors of JAK2 |
| AU2022388555A1 (en) | 2021-11-09 | 2024-05-02 | Ajax Therapeutics, Inc. | 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| WO2024130173A1 (fr) * | 2022-12-16 | 2024-06-20 | Immvention Therapeutix | Dérivés de benzimidazole |
| CN117003710A (zh) * | 2023-07-19 | 2023-11-07 | 镇江先锋植保科技有限公司 | 一种2-巯基-6-氯苯并恶唑的制备方法 |
| WO2025050125A1 (fr) | 2023-09-01 | 2025-03-06 | Immvention Therapeutix | Benzoxazolylamino benzoxazoles substitués |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007215247B2 (en) | 2006-02-10 | 2012-12-13 | Transtech Pharma, Llc | Benzazole derivatives, compositions, and methods of use as Aurora kinase inhibitors |
| WO2008153701A1 (fr) | 2007-05-24 | 2008-12-18 | Schering Corporation | Composés d'inhibition de l'activité de ksp kinésine |
| TWI453207B (zh) | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶，其組合物及使用其之治療方法 |
| US8759535B2 (en) | 2010-02-18 | 2014-06-24 | High Point Pharmaceuticals, Llc | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof |
| ES2679918T3 (es) | 2010-02-18 | 2018-08-31 | Vtv Therapeutics Llc | Derivados de imidazol condensados sustituidos, composiciones farmacéuticas y métodos de uso de los mismos |
| WO2012094580A2 (fr) * | 2011-01-07 | 2012-07-12 | High Point Pharmaceuticals, Llc | Composés capables de moduler le stress oxydatif |
| EP2992880A1 (fr) | 2014-09-04 | 2016-03-09 | Fundació Institut de Recerca de l'Hospital de la Santa Creu l Sant Pau | Utilisation d'inducteurs d'hème oxygénase -1 et du récepteur 2 de cannabinoïdes ou d'agonistes du récepteur opioïde delta dans la douleur inflammatoire |
| WO2016089648A1 (fr) * | 2014-12-01 | 2016-06-09 | Vtv Therapeutics Llc | Inhibiteurs de bach1 en combinaison avec des activateurs de nrf2 et compositions pharmaceutiques les contenant |
| GB201614314D0 (en) * | 2016-08-22 | 2016-10-05 | Discuva Ltd | Antibiotic compounds |
| US20220177460A1 (en) | 2019-04-12 | 2022-06-09 | Mitobridge Inc. | Hmox1 inducers |
-
2020
- 2020-04-08 US US17/602,584 patent/US20220177460A1/en active Pending
- 2020-04-08 EP EP20722177.1A patent/EP3952990A1/fr active Pending
- 2020-04-08 MA MA055607A patent/MA55607A/fr unknown
- 2020-04-08 IL IL287183A patent/IL287183B2/en unknown
- 2020-04-08 TW TW109111795A patent/TW202104211A/zh unknown
- 2020-04-08 PH PH1/2021/552348A patent/PH12021552348A1/en unknown
- 2020-04-08 SG SG11202110595YA patent/SG11202110595YA/en unknown
- 2020-04-08 AU AU2020271833A patent/AU2020271833A1/en active Pending
- 2020-04-08 JP JP2021559995A patent/JP2022527402A/ja active Pending
- 2020-04-08 CN CN202080038769.6A patent/CN113874074B/zh active Active
- 2020-04-08 CA CA3135615A patent/CA3135615A1/fr active Pending
- 2020-04-08 US US16/843,426 patent/US10766888B1/en active Active
- 2020-04-08 MX MX2021012466A patent/MX2021012466A/es unknown
- 2020-04-08 BR BR112021020055A patent/BR112021020055A2/pt unknown
- 2020-04-08 WO PCT/US2020/027240 patent/WO2020210339A1/fr not_active Ceased
- 2020-04-08 KR KR1020217037130A patent/KR20220010491A/ko active Pending
-
2021
- 2021-09-20 CO CONC2021/0012287A patent/CO2021012287A2/es unknown
-
2023
- 2023-10-06 US US18/377,606 patent/US12071433B2/en active Active
-
2024
- 2024-08-22 US US18/812,175 patent/US20240409533A1/en active Pending
- 2024-09-13 JP JP2024158735A patent/JP2024178242A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202104211A (zh) | 2021-02-01 |
| JP2024178242A (ja) | 2024-12-24 |
| US20240051952A1 (en) | 2024-02-15 |
| CN113874074B (zh) | 2024-11-01 |
| US10766888B1 (en) | 2020-09-08 |
| IL287183B2 (en) | 2025-01-01 |
| EP3952990A1 (fr) | 2022-02-16 |
| BR112021020055A2 (pt) | 2021-12-07 |
| US20240409533A1 (en) | 2024-12-12 |
| AU2020271833A8 (en) | 2022-01-06 |
| CN113874074A (zh) | 2021-12-31 |
| WO2020210339A1 (fr) | 2020-10-15 |
| CA3135615A1 (fr) | 2020-10-15 |
| JP2022527402A (ja) | 2022-06-01 |
| CO2021012287A2 (es) | 2021-09-30 |
| WO2020210339A8 (fr) | 2020-11-12 |
| SG11202110595YA (en) | 2021-10-28 |
| IL287183B1 (en) | 2024-09-01 |
| US20220177460A1 (en) | 2022-06-09 |
| PH12021552348A1 (en) | 2022-09-12 |
| MX2021012466A (es) | 2021-11-12 |
| IL287183A (en) | 2021-12-01 |
| KR20220010491A (ko) | 2022-01-25 |
| AU2020271833A1 (en) | 2021-11-11 |
| US12071433B2 (en) | 2024-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA55607A (fr) | Inducteurs de la ho-1 | |
| EP3994692C0 (fr) | Cellule binaire de calcul en mémoire | |
| EP3833739A4 (fr) | Souche d'akkermansia muciniphila | |
| PL3761790T3 (pl) | Pikolinoamidy jako fungicydy | |
| EP4012732A4 (fr) | Inducteur | |
| EP3919491C0 (fr) | Inhibiteur d'akt | |
| EP3967649C0 (fr) | Nanoparticule lipidique | |
| EP3742771C0 (fr) | Notification m2m sm-sr à sm-dp | |
| EP4034170A4 (fr) | Polypeptides apparentées au tgf-bêta | |
| EP3975220A4 (fr) | Panneau d'affichage | |
| EP3973348A4 (fr) | Visiocasques | |
| EP3957391C0 (fr) | Agitateur | |
| EP4082837A4 (fr) | Coffre de toit | |
| EP3965638C0 (fr) | Spéculum vaginal | |
| EP3962498A4 (fr) | Polythérapies | |
| EP3682831C0 (fr) | Applicateur cryogénique | |
| EP3912517C0 (fr) | Cadre | |
| EP4049824C0 (fr) | Moule | |
| EP4063289C0 (fr) | Capsule-couronne | |
| EP4012731A4 (fr) | Inducteur | |
| EP4011930A4 (fr) | Préimprégné | |
| DE202019004111U8 (de) | Weichenstellvorichtung | |
| EP4062972A4 (fr) | Dérivé de pyrazolomorphinane | |
| EP3990820A4 (fr) | Cryosphère | |
| EP4051872C0 (fr) | Pré-boulonnage |